healthy subjects obstructive sleep apnea (Bosentan is used in clinic in pulmonary hypertension)
Conditions
Interventions
Trade Name: Tracleer
Pharmaceutical Form: Tablet
INN or Proposed INN: Tracleer (bosentan)
Other descriptive name: bosentan
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration n
Sponsors
Hôpital Erasme
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: healthy male subjects: aged between 18 and 65 years, no medication male patients with obstructive sleep apnea (hypopnea/apnea index > 30) aged between 18 and 65 years Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: diabetes alcohol abuse cyclosporin use glyburide use hepatic disease women age
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: show if endothelin plays an important role in the control of ventilation in healthy subjects and obstructive sleep apnea patients.;Secondary Objective: better understanding of chemoreflex;Primary end point(s): dicrease in peripheric chemoreflex sensibility | — |
Countries
Belgium
Outcome results
None listed